Core Viewpoint - Pfizer Inc. is set to announce its fiscal fourth-quarter earnings for 2025, with expectations of a decline in profit per share compared to the previous year [1][2]. Financial Performance - Analysts predict Pfizer will report a profit of $0.56 per share on a diluted basis, which is an 11.1% decrease from $0.63 per share in the same quarter last year [2]. - For the full year, the expected EPS is $3.11, remaining unchanged from the previous year, but a decline of 4.8% to $2.96 is anticipated for fiscal 2026 [3]. Stock Performance - Pfizer's stock has underperformed the S&P 500 Index, which gained 16.2% over the past 52 weeks, with Pfizer shares down 5.3% during the same period [4]. - The stock also lagged behind the Health Care Select Sector SPDR Fund, which returned 11.6% [4]. Market Concerns - The underperformance of Pfizer's stock is attributed to concerns over patent expirations for key medications such as Eliquis and Ibrance, as well as declining sales from COVID-19 products [5]. Recent Earnings Report - On November 4, 2025, Pfizer reported its Q3 results, with an adjusted EPS of $0.87, surpassing Wall Street's expectation of $0.66. The company's revenue was $16.7 billion, exceeding forecasts of $16.6 billion [6]. Analyst Ratings - The consensus opinion on Pfizer stock is moderately bullish, with a "Moderate Buy" rating. Among 24 analysts, six recommend a "Strong Buy," one a "Moderate Buy," 16 a "Hold," and one a "Strong Sell." The average price target is $27.95, suggesting an 11% potential upside from current levels [7].

Core Insights - Pfizer Inc. is a global biopharmaceutical company with a market capitalization of approximately $146 billion, focusing on a diverse range of medicines and vaccines [2][3]. Company Overview - Founded 170 years ago, Pfizer is headquartered in New York and operates in over 125 countries, specializing in research, development, manufacturing, and marketing of pharmaceuticals [1]. - The company has faced challenges due to a decline in COVID-19 product demand but is committed to innovating and expanding its pipeline of treatments [2][3]. Stock Performance - Over the past three months, Pfizer's stock has increased by about 3.2%, underperforming compared to the Dow Jones Industrial Average, which returned 4.4% [4]. - The stock reached a 52-week high of $27.69 in October but has since decreased by approximately 7.2% from that peak [4]. - In the last 12 months, Pfizer's shares have seen a slight decline, with a 3.1% drop in 2025 alone, while the Dow Jones has gained 5.7% over the past year and 11.5% in 2025 [5]. Technical Indicators - Pfizer's shares have maintained levels above their 50-day and 200-day moving averages, indicating a potential shift in momentum [6]. Recent Developments - Concerns about upcoming patent expirations for key medications like Eliquis and Ibrance, along with declining COVID-19 product sales, have pressured the stock [7]. - A positive development occurred on November 21 when the FDA approved the combination of PADCEV and Keytruda for treating certain bladder cancer patients, leading to a nearly 2.6% increase in stock price [7].

Core Insights - The drugmaker reported a third-quarter profit of $3.93 billion, driven by increased sales of key drugs which helped to mitigate the impact of patent expirations [1] Financial Performance - The third-quarter profit reached $3.93 billion, indicating strong financial performance despite challenges [1] - Higher sales for key drugs were a significant factor contributing to the profit [1] Market Impact - The company successfully offset losses from patent expirations through strategic sales increases [1]